Novo Nordisk says a recent Phase 2 trial of monlunabant in diabetic kidney disease patients failed to meet its primary endpoint.
FDA warns Chinas Imperial Palace Commodity about CGMP violations in its manufacturing of over-the-counter drugs.
FDA warns Pompano Beach, FL-based BioStem Life Sciences that it is illegally marketing cellular products that also reflect CGMP violations.
FDA warns Chinas Center for Instrumental Analysis of China Pharmaceutical University about CGMP deviations in its work as a contract testing facility ...
FDA says a Trokamed recall updating instructions for its Mini PCNL sheath was Class 1.
FDA approves a Supernus Pharmaceuticals NDA for Onapgo (apomorphine hydrochloride) injection for treating motor fluctuations in adults with advanced P...
The Justice Department says C.R. Bard and three affiliates have agreed to pay $17 million to resolve a whistleblowers allegations that the firm used i...
Represented by Public Citizen Litigation Group, Doctors for America sues FDA and several other agencies over their removal of Web pages and datasets n...
